Document is current
Any future updates will be listed below
-
Authors
Del Rosso, James Q.
Pariser, David
Bhatia, Neal https://orcid.org/0000-0001-7448-7809
Deering, Kathleen L.
Harshaw, Qing
Barghout, Victoria
Ferro, Thomas J.
-
Funding
Funding for this research was provided by:
Sun Pharma
- License Information
-
More Information
Article History
Received: 19 September 2025
Accepted: 24 February 2026
First Online: 20 July 2026
Declarations
Conflict of interest: James Q. Del Rosso has served as a clinical research investigator, consultant/advisor, and/or speaker for AbbVie, Aclaris Therapeutics, Almirall, Amgen (Celgene), AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Athenex, Bausch Health (Ortho Dermatologics), Beiersdorf, Biofrontera, Biopharmix, Biorasi, BlueCreek Pharmaceuticals, Botanix Pharmaceuticals, Brickell Biotech, Bristol Myers Squibb, Cara Therapeutics, Cassiopea, Dermata Therapeutics, Dermavant Sciences, Encore, EPI Health, Evommune, Ferndale, Galderma, Genentech, Incyte, Janssen, Jem Health, La Roche-Posay, LEO Pharma, Lilly (Dermira), MC2 Therapeutics, Nektar Therapeutics, Novan, Nutrafol, Pfizer, Ralexar Therapeutics, Regeneron Pharmaceuticals, Sanofi, Sente, Sol-Gel Technologies, Sonoma Pharmaceuticals (Intraderm), Sun Pharma, UCB, Verrica Pharmaceuticals, and VYNE Therapeutics (Foamix/Menlo); he is president of the American Acne & Rosacea Society. David Pariser is an investigator for AbbVie, Apogee Therapeutics, LEO Pharma, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, Priovant Therapeutics, Regeneron Pharmaceuticals, and Veradermics, and he is on a data safety monitoring board for Bristol Myers Squibb. Neal Bhatia is an advisor, consultant, and investigator for AbbVie, Advanced Derm Solutions, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Botanix Pharmaceuticals, Bristol Myers Squibb, Galderma, Johnson & Johnson, Journey, La Roche-Posay, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sagimet Biosciences, Sanofi, Skinfix, Soligenix, Sun Pharma, and Verrica Pharmaceuticals. Kathleen L. Deering is an employee of EPI-Q and received payment from Sun Pharma associated with the development and execution of this study. Qing Harshaw was an employee of EPI-Q at the time of the study and received payment from Sun Pharma associated with the development and execution of this study. Victoria Barghout is CEO of Viver Health LLC, which receives funding from Bristol Myers Squibb, Novartis, Sun Pharma, and Taiho Pharmaceutical, and received payment from Sun Pharma associated with the development and execution of this study. Thomas J. Ferro is a former employee of Sun Pharmaceutical Industries, Inc. and a current employment of Data Loft, Inc.
Ethical Approval: This study protocol was reviewed and determined to be exempt by WIRB-Copernicus Group (WCG®) Institutional Review Board (protocol number 70-1059-001). Informed consent was obtained online from participants prior to study participation.
